Entero Therapeutics, Stock Today
ENTO Stock | 0.40 0.02 4.76% |
Performance0 of 100
| Odds Of DistressOver 85
|
Entero Therapeutics, is selling at 0.4 as of the 10th of September 2024; that is 4.76% down since the beginning of the trading day. The stock's open price was 0.42. Entero Therapeutics, has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Entero Therapeutics, symbol was changed from FWBI on 17th of May 2024. Equity ratings for Entero Therapeutics, are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 11th of August 2024 and ending today, the 10th of September 2024. Click here to learn more.
IPO Date 11th of October 2016 | Category Healthcare |
Entero Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. More on Entero Therapeutics,
Moving together with Entero Stock
0.71 | DTIL | Precision BioSciences | PairCorr |
0.63 | VIRI | Virios Therapeutics Llc | PairCorr |
0.79 | VIRX | Viracta Therapeutics | PairCorr |
Moving against Entero Stock
Entero Stock Highlights
Older Symbol | FWBI | |||||||||||||||||||||||||||||||||||||||||||||
CEO Chairman | RPh MBA | |||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Entero Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Entero Therapeutics,'s financial leverage. It provides some insight into what part of Entero Therapeutics,'s total assets is financed by creditors.
|
Entero Therapeutics, (ENTO) is traded on NASDAQ Exchange in USA. It is located in 777 Yamato Road, Boca Raton, FL, United States, 33431 and employs 9 people. Entero Therapeutics, was previously known as First Wave BioPharma and was traded on NASDAQ Exchange under the symbol FWBI. Entero Therapeutics, is listed under Pharmaceutical Products category by Fama And French industry classification. The company conducts business under Healthcare sector and is part of Biotechnology industry.
Entero Therapeutics, generates negative cash flow from operations
Check Entero Therapeutics, Probability Of Bankruptcy
Entero Therapeutics, Historical Income Statement
Entero Stock Against Markets
Entero Therapeutics, Corporate Management
Jennifer SealeyVoyksner | Senior Development | Profile | |
Sarah CPA | Chief Officer | Profile | |
Amy ChandlerSkerkis | QA Affairs | Profile | |
Martin MBA | Senior Development | Profile |
Additional Information and Resources on Investing in Entero Stock
When determining whether Entero Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entero Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entero Therapeutics, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entero Therapeutics, Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.